2024
Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML.
Gyurkocza B, Nath R, Seropian S, Choe H, Litzow M, Abboud C, Koshy N, Stiff P, Tomlinson B, Abhyankar S, Foran J, Hari P, Chen G, Al-Kadhimi Z, Kebriaei P, Sabloff M, Orozco J, Jamieson K, Silverman M, Van Besien K, Schuster M, Law A, Larkin K, Pandit-Taskar N, Rowley S, Munshi P, Cook R, Levy M, Lazarus H, Sandmaier B, Pagel J, Reddy V, MacDougall J, McNamara K, Spross J, Haeuber E, Vusirikala M, Nahar A, Desai A, Giralt S. Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML. Journal Of Clinical Oncology 2024, jco2302018. PMID: 39298738, DOI: 10.1200/jco.23.02018.Peer-Reviewed Original ResearchEvent-free survivalIntention-to-treat populationIntention-to-treatHazard ratioRR-AMLOverall survivalOlder patientsPhase III open-label trialEvent-free survival HRTreatment-related adverse eventsAllogeneic hematopoietic cell transplantationConventional careIncomplete platelet recoveryOS hazard ratioSecondary end pointsHematopoietic cell transplantationOpen-label trialConventional care groupPretransplant regimenRefractory AMLRelapsed/refractory AMLChemotherapy initiationDismal prognosisPlatelet recoveryCell transplantation
2009
Stem Cell Mobilization Using 5 Pm Dosing of Plerixafor.
Cooper D, Baker J, Medoff E, Pratt K, Conkling-Walsh A, Snyder E, Seropian S, Foss F. Stem Cell Mobilization Using 5 Pm Dosing of Plerixafor. Blood 2009, 114: 4233. DOI: 10.1182/blood.v114.22.4233.4233.Peer-Reviewed Original ResearchStem cell mobilizationPM dosingPoor mobilizersMultiple myelomaCell mobilizationG-CSFStem cell mobilizing agentsPrior mobilizationGerm cell tumorsOff-label useStem cellsStem cell collectionAutologous stem cellsEvening dosingFour patientsMedian WBCCell tumorsLabel usePlatelet recoveryPivotal studiesMedian numberPatientsCD34 cellsCell collectionDosing